CRISPR Therapeutics

147 articles with CRISPR Therapeutics

• CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

  8/5/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 2:30 p.m. ET.

• 

  A Pivotal Moment for CRISPR in the Gene Editing Journey

  8/4/2021

  With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
• 

  Vertex Hopes to Channel CF Drug Successes into Other Therapies in the Pipeline

  7/30/2021

  The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.

• CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

  7/29/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2021.

• 

  Jennifer Doudna Reacts to Intellia CRISPR Breakthrough, Outlines Challenges

  7/1/2021

  Jennifer Doudna is best known for discovering CRISPR/Cas9 gene editing with Emmanuelle Charpentier, and both winning the Nobel Prize in Chemistry in 2020.
• 

  UPDATED: In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body

  6/28/2021

  Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.

• CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia  

  6/15/2021

  CRISPR Therapeutics and Capsida Biotherapeutics Inc .today announced a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia.

• 

  CRISPR and Capsida Partner in Gene Edited Therapies for ALS, Friedreich's Ataxia

  6/15/2021

  Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.

• Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

  6/11/2021

  Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment.

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - May 25, 2021

  5/25/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June

• Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

  5/12/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress. Abstract #EP736 entitled “ CTX001 for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121

• CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

  5/6/2021

  Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Apr 29, 2021

  4/29/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May:

• CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

  4/28/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting, to be held in a virtual format from June 4 to 8, 2021.

• CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

  4/27/2021

  Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)

• Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

  4/26/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).

• Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

  4/20/2021

  Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001

• 

  Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics

  4/20/2021

  Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.

• CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

  4/10/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell program at the American Association for Cancer Research Annual Meeting 2021.

• CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

  4/6/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 9:30 a.m. ET.